Cited by 226Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment ApproachesHeart Failure Treatment and Management

B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis

Open access
Clavel, Marie-Annick, Malouf, Joseph, Michelena, Hector I., Suri, Rakesh M., Jaffe, Allan S., Mahoney, Douglas W., Enriquez-Sarano, Maurice·2014·Journal of the American College of Cardiology

Abstract

Objectives This study was conducted to define the association between serum B-type natriuretic peptide (BNP) activation and survival after the diagnosis of aortic stenosis (AS).Background In AS, the link between BNP levels and clinical outcome is in dispute. Failure to account for the normal shifting of BNP ranges with aging in men and women, not using hard endpoints (survival), and not enrolling large series of patients have contributed to the uncertainty.Methods A program of prospective measurement of BNP levels with Doppler echocardiographic AS assessment during the same episode of care was conducted. BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1 defined BNP clinical activation.Results In 1,953 consecutive patients with at least moderate AS (aortic valve area 1.03 ± 0.26 cm(2); mean gradient 36 ± 19 mm Hg), median BNP level was 252 pg/ml (interquartile range: 98 to 592 pg/ml); BNP ratio 2.46 (interquartile range 1.03 to 5.66); ejection fraction (EF) 57% ± 15%, and symptoms present in 60% of patients. After adjustment for all survival determinants, BNP clinical activation (BNP ratio >1) independently predicted mortality after diagnosis (p < 0.0001; hazard ratio [HR]: 1.91; 95% CI: 1.55 to 2.35) and provided incremental power to the survival predictive model (p < 0.0001). Eight-year survival was 62 ± 3% with normal BNP levels, 44 ± 3% with BNP ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to 1.90), 25 ± 4% with BNP ratio of 2 to 3 (adjusted HR: 2.12; 95% CI: 1.63 to 2.75), and 15 ± 2% with BNP ratio of ≥3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.05). This strong link to survival was confirmed in asymptomatic patients with normal EF (adjusted HR: 2.35 [95% CI: 1.57 to 3.56] for BNP clinical activation and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP ratio of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP ratio of ≥3). Aortic valve replacement was associated with survival improved by a similarly high margin (p = 0.54) with BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89; p = 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47 to 0.66; p < 0.0001).Conclusions In this large series of patients with AS, BNP clinical activation was associated with excess long-term mortality incrementally and independently of all baseline characteristics. Higher mortality with higher BNP clinical activation, even in asymptomatic patients, emphasizes the importance of appropriate clinical interpretation of BNP levels in managing patients with AS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2014.02.581

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevated levels of brain natriuretic peptide, cardiac troponin, and galectin-3 are correlated with all-cause mortality in individuals with CAVS.

    “Previous studies showed that elevated levels of brain natriuretic peptide, cardiac troponin, and galectin-3 are correlated with all-cause mortality in individuals with CAVS.6,7,8,9,10”

    From Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targets (2025) · cites this paper as [8]

    The Results (page not specified in the indexed copy) link elevated BNP to increased overall mortality in patients with moderate or severe aortic stenosis. The cited paper does not provide evidence for the claimed associations with cardiac troponin or galectin-3. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • A BNP ratio >1 is a powerful independent predictor of mortality in AS, even in asymptomatic patients.

    “A BNP ratio of >1 was found to be a powerful independent predictor of mortality in AS, even in patients with asymptomatic AS187.”

    From Calcific aortic stenosis (2016) · cites this paper as [187]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [16]16. Clavel et al. JACC Vol. 63, No. 19, 2014 BNP and Survival in Aortic Stenosis May 20, 2014:2016-25

Cited by

Sorted by citations

Authors
Clavel, M.-A., Malouf, J., Michelena, H. I., Suri, R. M., Jaffe, A. S., Mahoney, D. W., & Enriquez-Sarano, M.
Affiliations
Mayo Clinic (US)
Corresponding author
Enriquez-Sarano, Maurice
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2014-05
Volume
63
Issue
19
Pages
2016-2025
ISSN
0735-1097 (ISSN-L)
OpenAlex
W56250199
Cited by
226
References
48
Citations by year
2026: 15 · 2025: 19 · 2024: 10 · 2023: 20 · 2022: 19 · 2021: 16 · 2020: 29 · 2019: 19 · 2018: 17 · 2017: 24 · 2016: 17 · 2015: 15 · 2014: 5 · 2013: 1
FWCI
13.90
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Corpus Université Laval (Université Laval) (submittedVersion)
Funders
  • Canadian Institute of Health Research
  • Abbott Diagnostics
  • Edwards Lifesciences
  • St. Jude Medical
  • Sorin Group
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
brain natriuretic peptide, aortic stenosis, mortality prediction, survival after diagnosis, asymptomatic aortic stenosis, ejection fraction, Doppler echocardiography, prognostic factors, heart failure risk stratification, heart failure hospitalization, heart failure mortality, heart failure readmission
MeSH terms
Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Time Factors, Cohort Studies, Biomarkers, Survival Rate, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review